Slideshow

Impact of Canagliflozin on Renoprotection in T2DM

Author(s):

Veronica Hackethal MD

Will SGLT2 inhibitor canagliflozin prove renoprotective in T2DM patients? CANVAS study authors sought to find out.

Related Videos
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Related Content
The HCPFive: Top News for Healthcare Providers from the Week of 02/16 | Image Credit: HCPLive
February 22nd 2025

The HCPFive: Top News for Healthcare Providers from the Week of 02/16

HCPLive Editorial Staff
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
February 15th 2025

Diabetes Dialogue: Omnipod 5 and Medtronic 780G for Type 2 Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD | Image Credit: Mount Sinai
February 18th 2025

Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD

Connor Iapoce
Medical Ethics Unpacked: GLP-1 Allocation
February 5th 2025

Medical Ethics Unpacked: GLP-1 Allocation and Challenges of Equitable Access

Steve Levine, MD Dominic Sisti, PhD
CELZ-201 Cuts Insulin Dependency at 1 Year in Patients with Type 2 Diabetes | Image Credit: LinkedIn
February 11th 2025

CELZ-201 Cuts Insulin Dependency at 1 Year in Patients with Type 2 Diabetes

Connor Iapoce
Novo Nordisk | Credit: Novo Nordisk
February 5th 2025

Monlunabant Misses Primary Endpoint in Phase 2 Diabetic Kidney Disease Trial

Abigail Brooks, MA
© 2025 MJH Life Sciences

All rights reserved.